Related Experiment Video

Updated: Feb 8, 2026

Ex Vivo Organoid Model of Adenovirus-Cre Mediated Gene Deletions in Mouse Urothelial Cells
09:16

Ex Vivo Organoid Model of Adenovirus-Cre Mediated Gene Deletions in Mouse Urothelial Cells

Published on: May 5, 2022

3.1K

Immunotherapy Combinations and Sequences in Urothelial Cancer: Facts and Hopes

Alejo Rodriguez-Vida1, Jose Luis Perez-Gracia2, Joaquim Bellmunt3,4

  • 1Medical Oncology Department, Hospital del Mar, IMIM (Hospital del Mar Research Institute), Barcelona, Spain.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|July 12, 2018
PubMed

Insights

Immune checkpoint inhibitors (ICI) show promise for urothelial cancer but benefit only a subset of patients. Research focuses on combining ICI with chemotherapy, targeted agents, or radiotherapy to improve response rates and long-term remission.

Area of Science:

  • Oncology
  • Immunotherapy
  • Urothelial Carcinoma

Background:

  • Immune checkpoint inhibitors (ICI) represent a significant advancement in cancer therapy, demonstrating clinical benefits in various tumor types, including urothelial cancer.
  • However, monotherapy with ICI yields objective response rates of only 20-23%, leaving a substantial portion of patients without benefit.
  • While ICI improves response duration compared to chemotherapy, long-term remissions are achieved by only half of the responding patients.

Purpose of the Study:

  • To review current research on combining immune checkpoint inhibitors (ICI) with other therapeutic modalities in urothelial cancer.
  • To explore strategies aimed at increasing the number of patients who benefit from immunotherapy.
  • To highlight the development of biomarkers for personalized immunotherapy approaches.

Main Methods:

  • Review of ongoing research and clinical trials investigating combination therapies for urothelial cancer.
  • Analysis of strategies involving the combination of ICI with chemotherapy, targeted agents, other immunotherapies, and radiotherapy.
  • Examination of biomarker development for predicting immunotherapy response.

Main Results:

  • Monotherapy with ICI provides limited benefit to a significant proportion of urothelial cancer patients.
  • Combinatorial approaches are being actively investigated to enhance ICI efficacy.
  • Biomarker research is crucial for tailoring immunotherapy to individual patients.

Conclusions:

  • Combining immune checkpoint inhibitors (ICI) with other treatments like chemotherapy, targeted therapy, or radiotherapy holds promise for improving outcomes in urothelial cancer.
  • Personalized immunotherapy through biomarker development is essential for maximizing treatment benefits.
  • Further research into combination strategies is critical to overcome current limitations of ICI monotherapy.

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

419
Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis09:28

Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis

Published on: May 12, 2019

10.8K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Cis-regulatory Sequences02:02

Cis-regulatory Sequences

Cis-regulatory sequences are short fragments of non-coding DNA that are present on the same chromosomes as the genes that they regulate. These fragments serve as binding sites for transcriptional regulators, proteins that are responsible for controlling gene transcription and differential gene expression across cell types in eukaryotes. Cis-regulatory sequences can be close to the gene of interest or thousands of bases away in the DNA sequence; however, those sequences that are further away are...
11.9K
Sequences01:29

Sequences

Sequences are fundamental mathematical objects consisting of ordered lists of numbers that follow a specific rule or pattern. Sequences are critical in various mathematical concepts, including calculus, series, and number theory. They can model real-world phenomena such as population growth, financial investments, and physical processes like the diminishing height of a bouncing ball.Each number in a sequence is referred to as a term. Typically, the terms are denoted as a1, a2, a3,…, where...
280
Sanger Sequencing01:57

Sanger Sequencing

DNA sequencing is a fundamental technique that is routinely used in the biological sciences. This method can be applied to a range of questions at different scales - from the sequencing of a cloned DNA fragment or the study of a mutation in a gene up to whole-genome sequencing. However, despite the widespread use of sequencing today, it was not until 1977 that Fredrick Sanger and his collaborators developed the chain-termination method to decode DNA sequences. It relies on the separation of a...
774.8K
Arithmetic Sequences01:30

Arithmetic Sequences

An arithmetic sequence is a structured arrangement of numbers where each term is derived by adding a constant value, known as the common difference, to the previous term. This consistent pattern allows for the efficient computation of any term within the sequence as well as the cumulative sum of multiple terms. The formula for finding the nth term of an arithmetic sequence is:Here, aₙ represents the nth term of the sequence, a is the first term, d is the common difference, and n is the...
240
Next-generation Sequencing03:00

Next-generation Sequencing

The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
98.7K